Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

How accurate are stock forecasts?

Stock forecasts are based on technical and fundamental analysis but should not be considered as guaranteed predictions. Past performance does not guarantee future results.

How do I analyze ARCT stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate ARCT investment potential.

What is ARCT stock price today?

Get real-time ARCT stock price, historical data, and price charts on Financhill. Track ARCT performance with our advanced analysis tools.

Is ARCT a good investment?

Evaluate ARCT investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy ARCT stock?

To buy ARCT stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of ARCT?

View detailed market capitalization data and company valuation metrics for ARCT on our comprehensive analysis page.

What is the P/E ratio of ARCT?

Use our fundamental analysis tools to view ARCT P/E ratio and compare valuation metrics with industry peers.

What are ARCT earnings?

View ARCT earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Arcturus Therapeutics Holdings, Inc. Stock Predictions

Still Time to Get In: RAD Intel at $0.85/Share

DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi

Sell

ARCT
Arcturus Therapeutics Holdings, Inc.

Last Price:

$6.80

Seasonality Move:

3.23%

7 Day Trial

ALL ACCESS PASS

$ 7

This AI Layer Just Raised Its Share Price

Arcturus Therapeutics Holdings, Inc. Stock Forecast

Over the next 52 weeks, Arcturus Therapeutics Holdings, Inc. has on average historically risen by 44.6% based on the past 12 years of stock performance.
Arcturus Therapeutics Holdings, Inc. has risen higher in 4 of those 12 years over the subsequent 52-week period, corresponding to a historical accuracy of 33.33%
Is Arcturus Therapeutics Holdings, Inc. Stock Undervalued?

The current Arcturus Therapeutics Holdings, Inc. [ARCT] share price is $6.59. The Score for ARCT is 20, which is 60% below its historic median score of 50, and infers higher risk than normal.
ARCT is currently trading in the 10-20% percentile range relative to its historical Stock Score levels.

Will Arcturus Therapeutics Holdings, Inc. Stock Go Up Next Year?

Over the next 52 weeks, Arcturus Therapeutics Holdings, Inc. has on average historically risen by 44.6% based on the past 12 years of stock performance.

Arcturus Therapeutics Holdings, Inc. Stock Rating

Sell

Arcturus Therapeutics Holdings, Inc. (ARCT) is a Sell

Is Arcturus Therapeutics Holdings, Inc. overpriced?

Arcturus Therapeutics Holdings, Inc. has risen higher in 4 of those 12 years over the subsequent 52-week period, corresponding to a historical accuracy of 33.33%

Arcturus Therapeutics Holdings, Inc. Stock Price History

Is ARCT stock going to rise?

Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and ARCT is experiencing buying pressure, which is a positive indicator for future bullish movement.

Stock Information

Stock Info

Exchange:

NASDAQ

Country:

United States

Industry:

Biotechnology

Sector:

Health Care

Type:

stock

Website:

arcturusrx.com

52-Week Data

52-Week High:

24.17

52-Week Low:

5.85

Prediction Charts

Market Cap:

187.2M

Price in USD:

6.59

Volume:

808.4K

Beta:

2.50

Technical Analysis

SMA50:

13.24

SMA100:

14.66

SMA200:

13.74

52-Wk Change:

-63.18%

Stock Predictions

Is Arcturus Therapeutics Holdings, Inc. stock public?

Yes, Arcturus Therapeutics Holdings, Inc. is a publicly traded company.
What is the Arcturus Therapeutics Holdings, Inc. stock quote today?

The Arcturus Therapeutics Holdings, Inc. stock price is 6.59 USD today.
How to buy Arcturus Therapeutics Holdings, Inc. stock online?

You can buy Arcturus Therapeutics Holdings, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date	Opening	Closing	Minimum	Maximum
Nov-13	8.03	7.77	8.22	7.76
Nov-14	7.44	7.27	7.65	7.26
Nov-17	7.26	6.76	7.32	6.72
Nov-18	6.71	6.62	6.82	6.57
Nov-19	6.66	6.04	6.69	6.02
Nov-20	6.23	5.90	6.38	5.85
Nov-21	5.93	6.26	6.49	5.90
Nov-24	6.28	6.33	6.38	6.07
Nov-25	6.43	6.80	6.84	6.32
Nov-26	6.83	6.80	6.90	6.60
Nov-28	6.83	6.79	6.90	6.75
Dec-1	6.62	6.49	6.75	6.35
Dec-2	6.51	6.25	6.51	6.07
Dec-3	6.30	6.59	6.61	6.23

Arcturus Therapeutics Holdings, Inc. Earnings

Arcturus Therapeutics Holdings, Inc. Earnings Report: Per Share Arcturus Therapeutics Holdings, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.

Arcturus Therapeutics Holdings, Inc. Forecast Revenue Growth

Arcturus Therapeutics Holdings, Inc. Stock Analysis: Historical quarterly revenues per share for Arcturus Therapeutics Holdings, Inc. and historical quarterly revenue growth:

Analysts estimate an earnings increase this quarter of $0.36 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.30 per share, and a decrease next year of $0.43 per share.

* Arcturus Therapeutics Holdings, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.